References
- Hanuš LO, Meyer SM, Muñoz E, et al. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33(12):1357–1392.
- FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. 2018. FDA Press Release. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms
- Gill LL. CBD Goes Mainstream. Consumer Reports. 2019 [cited 2019 Nov 11]. Available from: https://www.consumerreports.org/cbd/cbd-goes-mainstream/
- Corroon J, Phillips JA. A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res. 2018;3(1):152– 161.
- Mead A. Legal and regulatory issues governing cannabis and cannabis-derived products in the United States. Front Plant Sci. 2019;10:697.
- Bonn-Miller MO, Loflin MJE, Thomas BF, et al. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318(17):1708–1709.
- Meng Q, Buchanan B, Zuccolo J, et al. A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products. PLoS One. 2018;13(5):e0196396.
- Hazenkamp A. The trouble with CBD oil. Med Cannabis Cannabinoids. 2018;1:65–72.
- Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770–1804.
- Harvey DJ, Samara E, Mechoulam R. Urinary metabolites of cannabidiol in dog, rat and man and their identification by gas chromatography-mass spectrometry. J Chromatogr. 1991;562(1-2):299–322.
- Taylor L, Gidal B, Blakey G, et al. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053–1067.
- ElSohly MA, Murphy TP, Shahzadi I, et al. Screening and quantitation of Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) from different commercial products using GC-FID. Poster presentation SOFT 2019.
- Andrews R, Paterson S. Production of identical retention times and mass spectra for {delta}9-tetrahydrocannabinol and cannabidiol following derivatization with trifluoracetic anhydride with 1,1,1,3,3,3-hexafluoroisopropanol. J Anal Toxicol. 2012;36(1):61–65.
- Orion GMP Solutions CannaChemist. Cannabis chemistry: conversion of THC to CBD. Available from: http://hemphacker.com/conversion-thc-cbd/ [cited 2019 Feb 1].
- Djura P, Stierle DB, Sullivan B, et al. Some metabolites of the marine sponges Smenospongia aurea and Smenospongia echina. J Org Chem. 1980;45(8):1435–1141.
- Dixon DD, Lockner JW, Zhou Q, et al. Scalable, divergent synthesis of meroterpenoids via “borono-sclareolide”. J Am Chem Soc. 2012;134(20):8432–8435.
- Kulig K. Interpretation of workplace tests for cannabinoids. J Med Toxicol. 2017;13(1):106–110.
- Pacifici R, Pichini S, Pellegrini M, et al. THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of “light cannabis”. Clin Chem Lab Med. 2020;58(5):682–689.
- Pichini S, Mannocchi G, Berretta P, et al. Δ9-Tetrahydrocannabinol and cannabidiol time courses in the sera of "Light Cannabis" smokers: discriminating light cannabis use from illegal and medical cannabis use. Ther Drug Monit. 2020;42(1):151–156.
- Spindle TR, Cone EJ, Kuntz D, et al. Urinary pharmacokinetic profile of cannabinoids following administration of vaporized and oral cannabidiol and vaporized CBD-dominant cannabis. J Anal Toxicol. 2020;44(2):109–125.
- Ujváry I, Hanuš L. Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res. 2016;1(1):90–101.
- Toennes SW, Hanisch S, Pogoda W, et al. Pitfall in cannabinoid analysis-detection of a previously unrecognized interfering compound in human serum. Anal Bioanal Chem. 2015;407(2):463–470.
- Hanisch S, Paulke A, Toennes SW. Investigation of a recently detected THCCOOH isomer: Post mortem findings and comparison with Δ(8)-THCCOOH. Forensic Sci Int. 2015;257:252–256.
- Hanisch S, Paulke A, Toennes SW. Investigation of a recently detected 11-nor-9-carboxy-Δ(9)-tetrahydrocannabinol isomer: studies on the degradation of 11-nor-9-carboxy-Δ(9)-tetrahydrocannabinol glucuronide. J Pharm Biomed Anal. 2016;129:294– 298.
- Hanisch S, Paulke A, Toennes SW. 11-nor-9-carboxy-Δ9-tetrahydrocannabinol glucuronide exhibits acyl-migration isomers. J Pharm Biomed Anal. 2017;146:261–265.
- Kraemer M, Broecker S, Madea B, et al. Decarbonylation: a metabolic pathway of cannabidiol in humans. Drug Test Anal. 2019;11(7):957–967.
- Watanabe K, Usami N, Osada S, et al. Cannabidiol metabolism revisited: tentative identification of novel decarbonylated metabolites of cannabidiol formed by human liver microsomes and recombinant cytochrome P450 3A4. Forensic Toxicol. 2019;37(2):449–455.